About Otsuka
Otsuka is a company based in Chiyoda (Japan) founded in 1921. The company has 35,340 employees. Otsuka has completed 8 acquisitions, including Astex Pharmaceuticals, Avanir and Daiya Foods. Otsuka offers products and services including Medications and Functional Beverages.
- Headquarter Chiyoda, Japan
- Employees 35,340
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website otsuka.com/jp
- Legal Name Otsuka Holdings Co., Ltd.
- Annual Revenue₹26.4 Lakh
FY 2022 · -33% YoY
- Net Loss-₹6.84 Cr
FY 2022 · -2588% margin
- EBITDA-₹6.74 Cr
FY 2022 · -2549% margin
- Investors
- Employee Count35,340
- Investments & AcquisitionsAstex Pharmaceuticals
& 7 more
Associated legal entities of Otsuka
Otsuka operates through Otsuka Foods India Private Limited (dissolved under section 59(8)). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2022) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Otsuka Foods India Private Limited CIN U15549KA2018FTC113490 | Dissolved Under Section 59(8) | 28 May 2018 | Bengaluru, Karnataka | ₹0.3 Cr | – | 2 | View details |
Products & Services of Otsuka
Otsuka offers a comprehensive portfolio of products and services, including Medications and Functional Beverages.
Innovative medications are developed and supplied for various health applications
Functional beverages and foods are produced to support nutritional needs worldwide
Funding Insights of Otsuka
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Otsuka with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2021 | – | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Otsuka
Otsuka has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for Otsuka
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Otsuka Foods India Private Limited (Otsuka)
Otsuka Foods India Private Limited is the primary company behind Otsuka. The board of Otsuka Foods India Private Limited currently have 2 directors; the longest-serving is Hirokazu Uematsu, appointed in 2018. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Hirokazu Uematsu DIN 08144176 | Managing Director | 28 May 2018 | 8 yrs 4 mo | Otsuka Foods India Private Limited |
| Takuya Okamoto DIN 08799435 | Director | 19 Aug 2020 | 6 yrs 1 mo | Otsuka Foods India Private Limited |
People of Otsuka
97 people are tracked at Otsuka (41 in leadership, 17 in board & advisors, 39 in team); the tracked headcount is 35,340.
| Name | Role | Group |
|---|---|---|
Tatsuo Higuchi | CEO & President | Leadership |
Yuko Makino | CFO | Leadership |
Noriko Tojo | Executive Director | Leadership |
Shuichi Takagi | Executive Director | Leadership |
Yoshiro Matsuo | Executive Deputy President & Director | Leadership |
Makoto Inoue | Representative Director & COO | Leadership |
Chikako Usami | VP, Pharmaceutical Business Division Project Coordinator | Leadership |
Masayuki Kobayashi | Executive Director | Leadership |
Koichi Shiraishi | VP, Nutraceuticals Business, China | Leadership |
Titus Divala M.D. Fcphp | Director, Global Clinical Development | Leadership |
Masayuki Sato | VP & Director, Portfolio Management Office & Public Relations | Leadership |
Naoshi Satou | SVP & Associate GM, Nutraceuticals Division & Director, Social Health Relations Department | Leadership |
Mohamed Saleh | Quality System Operation Head | Leadership |
Yoshimi Kuroiwa | 創薬モダリティ研究所 所長 Head Of Department, Department Of Drug Modality Development | Leadership |
Tomoyuki Murata | Director, Global Compliance | Leadership |
Ryo Harima | VP, Deputy GM, Production & Purchasing | Leadership |
Takeshi Watanabe | VP, Director, Department of Business Development | Leadership |
Lyo Inuyama | EVP & Director, Medical Affairs, PV | Leadership |
Yoshihiro Yoshinaga | VP & Director, Regulatory Affairs Department & Administration Department | Leadership |
Masanori Udagawa | VP & Director, Corporate IT Department & Otsuka Holdings | Leadership |
77 more people are available in the full profile.
Complete people profiles for Otsuka
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Otsuka
Otsuka is a publicly listed company on the TSE with ticker symbol 4578 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Dec 2010
- Listed onTSE: 4578
- Listed entityOtsuka Holdings Co., Ltd.
- Exchange sectorHealth technology
- ISINJP3188220002
- Share price11,665.00 JPY (-0.13% on the day) · 2026-10-09
- Market capitalisation6,125,005,713,196.00 JPY
- Price to earnings15.2
- EPS (diluted, trailing year)768.11 JPY
- Dividend yield1.46%
- Volume (last session)1,476,700
Financials of Otsuka
Figures of Otsuka Foods India Private Limited, the primary company behind Otsuka, for FY 2022. Revenue was ₹26.4 Lakh (-33% year on year). Net loss was -₹6.84 Cr (-2588% margin). EBITDA was -₹6.74 Cr (-2549% margin). Revenue has grown at a compounded annual rate of -11% over three years.
- ₹26.4 LakhRevenue · FY 2022 · -33% YoY
- -₹6.84 CrNet loss · -2588% margin
- -₹6.74 CrEBITDA · -2549% margin
- ₹17.25 CrPaid-up capital
- -11%Revenue CAGR, 3 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2,470.00B JPY | 363.15B JPY | 528.60B JPY |
| 2024 | 2,330.00B JPY | 343.12B JPY | 504.83B JPY |
| 2023 | 2,020.00B JPY | 121.62B JPY | 389.97B JPY |
| 2022 | 1,740.00B JPY | 133.91B JPY | 262.90B JPY |
| 2021 | 1,500.00B JPY | 125.46B JPY | 233.48B JPY |
Balance sheet, profit and loss, cash flow and ratios of Otsuka Foods India Private Limited are on its company page.
Detailed financial statements for Otsuka
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Otsuka
Otsuka has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Astex Pharmaceuticals, Avanir and Daiya Foods.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of monoclonal antibodies against infectious diseases | visterrainc.com | Cambridge, United States | 2007 | Jul 2018 | $430M | |
Ultrasound-based renal denervation is applied for hypertension treatment. | recormedical.com | Palo Alto, United States | 2009 | Jul 2018 | •••• | |
Dairy-free cheese alternatives are produced and marketed by Daiya Foods. | daiyafoods.com | Vancouver, Canada | 2008 | Jul 2017 | $324M | |
Neurochemical modulators for ADHD treatment are developed by Neurovance. | neurovance.com | Cambridge, United States | 2011 | Mar 2017 | $100M | |
Novel therapeutics for CNS disorders are acquired, developed, and commercialized. | avanir.com | Aliso Viejo, United States | 1988 | Dec 2014 | $3.5B | |
Speciality pharma comany focused on drug discovery and development with focus on cancer and CNS disorders | astx.com | Pleasanton, United States | 1991 | Sep 2013 | $886M | |
Functional foods and supplements manufacturer | nutritionetsante.com | Revel, France | 1972 | Dec 2008 | •••• | |
Dietary supplements and soy-based snack bars are manufactured and marketed. | pharmavite.com | Northridge, United States | 1971 | Jan 1989 | •••• |
Complete acquisition details for Otsuka
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Otsuka
11 dated milestones of Otsuka across 100 years, from founding to its latest funding, stage changes and deals.
- Founded Otsuka is founded.
- Acquisition Acquires Pharmavite.
- Acquisition Acquires Nutrition & sante.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Astex Pharmaceuticals.
- Acquisition Acquires Avanir.
- Acquisition Acquires Neurovance.
- Acquisition Acquires Daiya Foods.
- Acquisition Acquires ReCor Medical.
- Acquisition Acquires Visterra.
- Funding First funding round.
Web traffic of Otsuka
The website of Otsuka (otsuka.com) receives about 47.2K visits a month and ranks #682,452 among all websites worldwide, #762 in Biotechnology and Pharmaceuticals.
- Monthly visits47.2K
▼ 1.2% vs previous month
- Unique visitors21.3K
per month
- Global rank#682,452
among all websites
- Category rank#762
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit2.0
- Average visit57 sec
- DevicesDesktop 52% · Mobile 48%
Websites whose visitors overlap most with Otsuka. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| chugai-pharm.co.jp | 100% | 180.8K | #220,597 | View details | |
| otsukakj.jp | 89% | – | #334,371 | View details | |
investor.lundbeck.com | investor.lundbeck.com | 86% | – | – | – |
| mt-pharma.co.jp | 84% | 18.4K | #158,674 | View details | |
| otsuka-us.com | 82% | 105.4K | #434,587 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 33 similar websites and full traffic analytics for Otsuka
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 33 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Otsuka
Complete news archive for Otsuka
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Otsuka
10 companies that operate in the same segment as Otsuka (Traditional Health & Nutrition), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | – | USD 3.02 B | 8,300 | |
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | – | USD 5.1 B | 13,500 | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | Petah Tikva, Central District, Israel | USD 500 M | USD 18.74 B | 51,792 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | – | USD 508.93 M | 5,180 | |
Pharmaceutical products are developed and marketed globally. | 2009 | Montville, New Jersey, United States | USD 155.92 M | – | – | |
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | – | USD 6.21 B | 25,870 | |
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations | 1991 | Delhi, Delhi, India | USD 367.2 M | USD 1.52 B | 21,320 | |
Generics, biosimilars, APIs, and vaccines are manufactured by Wockhardt. | 1967 | Mumbai, Maharashtra, India | – | USD 353.53 M | 3,410 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Otsuka
Otsuka was founded in 1921 and raised its 1st funding round 100 years after it was founded.
Otsuka is headquartered in Chiyoda, Japan. It is registered at Chiyoda, Tokyo, Japan.
Tatsuo Higuchi is the current CEO of Otsuka.
Otsuka has 35,340 employees.
The primary company behind Otsuka, Otsuka Foods India Private Limited, reported revenue of ₹26.4 Lakh for FY 2022, down 33% year on year.
Otsuka was founded in 1921 in Chiyoda City, Japan, as a manufacturer in the pharmaceutical and nutraceutical sectors. Generic drugs are produced and distributed, targeting central nervous system, cardiovascular, oncology, and ophthalmology areas. Avanir Pharmaceuticals, a US firm, was acquired in January 2015 to expand operations. Nutraceutical offerings include electrolyte rehydration drinks, balanced nutrition foods, and soy-based products. Revenues reached 13.21 billion with 1.02 billion in net profit for 2022.
Otsuka offers Medications and Functional Beverages.
Yes, Otsuka is publicly traded on TSE under the ticker symbol 4578.
Otsuka has made 8 acquisitions, including Astex Pharmaceuticals, Avanir, and Daiya Foods.
Otsuka has 1 investor. Key investors include Gates Foundation.
Otsuka operates through Otsuka Foods India Private Limited.
The legal entities of Otsuka currently have 2 directors, including Hirokazu Uematsu, Takuya Okamoto.